06.18.25 -- How A Biotech Navigates The CDMO Frenzy For GLP-1 Services

Join this webinar to explore USP <382>, effective December 1, 2025, covering required testing for elastomeric closures in parenteral drugs. Learn about compliance, instrumentation needs, and testing strategies, with expert guidance from Alcami. Click here to learn more.

In your CDMO search, prioritize finding a partner who recognizes impurity control as a critical component of patient-focused drug development and offers the necessary capabilities to ensure it.

A recent project applied an improvement methodology to the process validation step, ultimately providing not only an optimized and robust process but also an economic advantage.

Leveraging incurred sample reanalysis (ISR) in quality control helps your team mitigate risks, establish regulatory compliance, and instill confidence in your pharmacokinetic modeling.

The federal workforce reductions pose significant challenges for the life sciences industry, particularly for R&D, supply chain oversight, and industry workforce development.

Explore key parameters for choosing the right particle engineering approach to meet dry powder inhaler (DPI) target product profiles for inhalation-based drug products.

Review this case to learn how one solid dispersion technology lowered patients' pill burdens and demonstrated an improved therapeutic response for Galeterone.

Discover how moving bed technology can revolutionize your purification processes by enhancing efficiency, reducing costs, and promoting sustainable practices.

We develop robust, scalable formulations using a science-driven approach and quality-by-design principles to reduce risk, cost, and time.

Providing comprehensive solutions for Dry Powder Inhalers (DPIs), encompassing all stages from initial formulation screening to clinical-scale manufacturing.

Offering end-to-end drug product development and manufacturing across a global network, with no added project costs and no need for tech transfer throughout the product lifecycle.